Adding value to your assets, our aim

Our aim

Our aim is to find a use for existing advanced small molecules in the therapeutic treatment of atopic dermatitis, psoriasis, actinic keratosis, acne, and related dermatological diseases.

We are looking for compounds addressing a specific target or pathway in a selective manner with a scientific rationale that supports their use on one or more indications of interest. More specifically, Research compounds that have shown a good potency and an acceptable pharmacokinetic profile or Development compounds that have shown a good human safety profile

Who is this for

This call is addressed to scientists affiliated to Universities, Research Centers, Start-ups, Biotechs, and Pharmaceutical companies.

Collaborative framework

  • We offer to characterise your compund on key dermatological assays in vitro and in vivo
  • Intellectual property rights remain with the applicant
    • No need to disclose the chemical structure of your compound
    • All data and results generated will be treated as strictly confidential and will only be used to decide about future collaboration options
    • You will be the owner of the results obtained
    • We expect you not to patent, register, or communicate to any third party the results we generated whilst we are collaborating
  • A designated contact person will help you should you have questions

Collaboration process

  • Proposal submission
    • The first step is for you to create an account in AlmirallShare Innovation platform which is a secure site to store and manage your proposals
    • You can submit your proposal at any time
    • All the initial information provided under the proposal should be non-confidential. Please do not reveal the chemical structure of your compound, even if it is published
    • Please include an outline of your proposal (max. 300 words) and a detailed description of your advanced compound properties, including at least biological data such as target and affinities (IC50, Ki…etc), and available ADME data
  • Submissions will be handled following all applicable local compliance rules
  • Proposal evaluation and selection
    • A team of Almirall experts will evaluate your proposal
    • You will receive in writing Almirall’s decision regarding your proposal within 4-8 weeks after submission
    • If your proposal has been selected, a member of the Shared Innovation Team will reach out to you to initiate a collaboration agreement
    • Compounds will be tested in a pre-agreed panel of relevant cellular assays and in vivo disease models within a period of 4-6 months, starting upon MTA signature. This panel could be complemented with other assays, such as physicochemical properties and pharmacokinetic studies

For scientists at Universities, Research Centers, Start-ups, Biotechs and Pharma companies

Submit your proposal at any time